LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX)

18 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q3 2022.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.45M shares of 26.3M outstanding shares and own 28.32% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (3.33M shares), Redmile Group, LLC (2.82M shares), SILVERARC CAPITAL MANAGEMENT, LLC (611K shares), AXA S.A. (229K shares), Artal Group S.A. (200K shares), Alpha Wave Global, LP (121K shares), UBS OCONNOR LLC (75K shares), MILLENNIUM MANAGEMENT LLC (39.2K shares), CANNELL CAPITAL LLC (18K shares), and GEODE CAPITAL MANAGEMENT, LLC (11.1K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.